MEI Pharma, Inc.
http://www.meipharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MEI Pharma, Inc.
Scorpion Sinks Pincers Into Funding Round For PI3K Inhibitor
The oncology-focused start-up announced it closed a $150m series C financing that it plans to use to advance STX-478.
New Oncologics Overwhelmingly Approved In US Before EU
Ninety-five percent of novel cancer treatments approved in both the US and Europe received the FDA’s OK first, but Europe usually followed within a year, a Pink Sheet analysis shows.
Pharma Looks To America First: US FDA Holds Overwhelming Lead Over EMA In Novel Approvals
A Pink Sheet analysis finds US approval preceded European Union clearance for 80% of products approved in both areas, but when EU approval came first, it beat the FDA by a median of 13 months. US-first approvals came close to six months before the EU.
Coherus All But Checks Out Of Biosimilars With Meitheal Adalimumab Deal
Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Glycotex, Inc.
- Marshall Edwards, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice